---
title: 'Series 3: Regulatory statistics'
author: "Giusi Moffa"
date: '2017-11-24'
image: "jclub/img/nakedEmperor.jpg"
description: Figure from abovethelaw.com
output:
  html_document: default
  pdf_document: default
draft: false
type: "post"
bibliography: jclub.bib
---



<p><em><a href="https://abovethelaw.com/2017/10/when-the-emperor-has-no-clothes-3-tips-to-avoid-inadvertent-naked-licenses-under-trademark-law/">Figure from abovethelaw.com</a></em></p>
<!-- November 2nd 2017 -->
<table class="table table-striped table-hover" style="margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:left;">
Date
</th>
<th style="text-align:left;">
Location
</th>
<th style="text-align:left;">
Topic
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;width: 8em; ">
January 11th 2018
</td>
<td style="text-align:left;width: 8em; ">
CEB
</td>
<td style="text-align:left;width: 16em; ">
<a href="http://www.ich.org/ichnews/newsroom/read/article/ich-e9r1-revised-guideline-reaches-step-2b-of-the-ich-process.html">ICH E9 Addendum</a> and <a href="http://www.nejm.org/doi/full/10.1056/NEJMsm1605385?query=featured_clinical-trials">Per-Protocol Analyses of Pragmatic Trials</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
February 8th 2018
</td>
<td style="text-align:left;width: 8em; ">
Swiss TPH
</td>
<td style="text-align:left;width: 16em; ">
<a href="http://www.tandfonline.com/doi/full/10.1080/19466315.2017.1302358?af=R">Estimands and Their Role in Clinical Trials</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
March 8th 2018
</td>
<td style="text-align:left;width: 8em; ">
CEB
</td>
<td style="text-align:left;width: 16em; ">
<a href="http://onlinelibrary.wiley.com/doi/10.1002/sim.6841/full">A taxonomy of estimands for regulatory clinical trials with discontinuations</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
April 12th 2018
</td>
<td style="text-align:left;width: 8em; ">
Swiss TPH
</td>
<td style="text-align:left;width: 16em; ">
<a href="http://onlinelibrary.wiley.com/doi/10.1002/sim.7033/full">Estimands in clinical trials broadening the perspective</a> (possibly with comments)
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
May 17th 2018
</td>
<td style="text-align:left;width: 8em; ">
CEB
</td>
<td style="text-align:left;width: 16em; ">
<a href="https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm536750.pdf">Multiple Endpoints in Clinical Trials: FDA Issues Draft Guidance</a> (Parts I to III)
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
June 14th 2018
</td>
<td style="text-align:left;width: 8em; ">
Swiss TPH
</td>
<td style="text-align:left;width: 16em; ">
<a href="https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm536750.pdf">Multiple Endpoints in Clinical Trials: FDA Issues Draft Guidance</a> (Parts IV to V)
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
August 16th 2018
</td>
<td style="text-align:left;width: 8em; ">
CEB
</td>
<td style="text-align:left;width: 16em; ">
TBD
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
September 13th 2018
</td>
<td style="text-align:left;width: 8em; ">
Swiss TPH
</td>
<td style="text-align:left;width: 16em; ">
TBD
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
October 18th 2018
</td>
<td style="text-align:left;width: 8em; ">
CEB
</td>
<td style="text-align:left;width: 16em; ">
TBD
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
November 15th 2018
</td>
<td style="text-align:left;width: 8em; ">
Swiss TPH
</td>
<td style="text-align:left;width: 16em; ">
TBD
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
December 13th 2018
</td>
<td style="text-align:left;width: 8em; ">
CEB
</td>
<td style="text-align:left;width: 16em; ">
TBD
</td>
</tr>
</tbody>
</table>
<p> </p>
<p><em>Following up on the 2nd EFSPI Workshop on Regulatory Statistics, on October 5-6th 2017 in Basel</em></p>
<div id="regulatory-guidelines-around-multiple-endpoints" class="section level4">
<h4>Regulatory guidelines around multiple endpoints</h4>
<ul>
<li><a href="https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm536750.pdf">Multiple Endpoints in Clinical Trials: FDA Issues Draft Guidance</a><br />
<a href="http://raps.org/Regulatory-Focus/News/2017/01/12/26574/Multiple-Endpoints-in-Clinical-Trials-FDA-Issues-Draft-Guidance/">Announcement on RAPS (Regulatory Affairs Professionals Society )</a><br />
</li>
<li><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/03/WC500224998.pdf">EMA Guideline on multiplicity issues in clinical trials Draft</a></li>
</ul>
<p> </p>
</div>
<div id="update-of-the-ich-e9-to-include-the-concept-and-semantics-of-estimands" class="section level4">
<h4>Update of the ICH E9 to include the concept and semantics of estimands</h4>
<ul>
<li><a href="http://www.ich.org/ichnews/newsroom/read/article/ich-e9r1-revised-guideline-reaches-step-2b-of-the-ich-process.html">ICH E9 Addendum</a></li>
<li><a href="http://www.nejm.org/doi/full/10.1056/NEJMsm1605385?query=featured_clinical-trials">Per-Protocol Analyses of Pragmatic Trials</a><br />
Miguel A. Hernán and James M. Robins<br />
Statistics in Medicine, 2017</li>
<li><a href="http://www.tandfonline.com/doi/full/10.1080/19466315.2017.1302358?af=R">Estimands and Their Role in Clinical Trials</a><br />
Mouna Akacha, Frank Bretz, David Ohlssen, Gerd Rosenkranz &amp; Heinz Schmidli<br />
Statistics in Biopharmaceutical Research, 2017<br />
</li>
<li><a href="http://onlinelibrary.wiley.com/doi/10.1002/sim.6841/full">A taxonomy of estimands for regulatory clinical trials with discontinuations</a><br />
Thomas Permutt<br />
Statistics in Medicine, 2015<br />
</li>
<li><a href="http://onlinelibrary.wiley.com/doi/10.1002/sim.7033/full">Estimands in clinical trials broadening the perspective</a> <a href="http://onlinelibrary.wiley.com/doi/10.1002/sim.7033/pdf">[pdf]</a><br />
Mouna Akacha, Frank Bretz, Stephen Ruberg<br />
Statistics in Medicine, 2016<br />
with <em>Comments on Estimands in clinical trials broadening the perspective</em> by<br />
<a href="http://onlinelibrary.wiley.com/doi/10.1002/sim.7160/full">Thomas Permutt</a> <a href="http://onlinelibrary.wiley.com/doi/10.1002/sim.7160/epdf">[pdf]</a><br />
<a href="http://onlinelibrary.wiley.com/doi/10.1002/sim.7162/full">Peter Bauer</a> <a href="http://onlinelibrary.wiley.com/doi/10.1002/sim.7162/epdf">[pdf]</a><br />
<a href="http://onlinelibrary.wiley.com/doi/10.1002/sim.7164/full">Frank Rockhold</a> <a href="http://onlinelibrary.wiley.com/doi/10.1002/sim.7164/epdf">[pdf]</a><br />
</li>
<li><a href="http://onlinelibrary.wiley.com/doi/10.1002/sim.7163/full">Editorial: Estimands in clinical trials - a challenge to intention to treat?</a><br />
<a href="http://onlinelibrary.wiley.com/doi/10.1002/sim.7163/epdf">[pdf]</a><br />
Simon Day, 2016</li>
</ul>
<!-- * [Cytel - Estimands 101: Interview with Mouna Akacha](http://www.cytel.com/blog/estimands-101) -->
</div>
